Hemostemix Inc.

Recent News

  • Hemostemix Announces Warrant Repricing and Extension

    Calgary, Alberta--(Newsfile Corp. - May 6, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ‎‎(FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce that it has, subject to TSX Venture Exchange Approval, repriced to $0.55 each, and extended the exercise period for two years, the Warrants expiring May 7, 2020 and May 28, 2020, subject to the accelerator provisions, such that the exercise period of Warrants will be reduced to thirty (30) days, if, for any ten consecutive trading...

    2021-05-06 8:38 PM EDT
  • Hemostemix Provides a Clinical Trial Update and Announces the Release and Filing of 2020 Year-end Audited Financial Statements and Management Discussion and Analysis

    Calgary, Alberta--(Newsfile Corp. - April 30, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ‎‎(FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that, with the last patient follow up completed in April, the Company is now focusing its efforts on completing the key areas of the trial including, but not limited to, data entry, source document verification, data base query management and validation as more fully described below, biostatistical analyses and final reporting documentation. This process...

    2021-04-30 10:22 PM EDT
  • Hemostemix Reprices and Amends the Terms of Its Unit Offering and Debenture Offering

    Calgary, Alberta--(Newsfile Corp. - April 26, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) ‎‎(FSE: 2VFO.F) ("Hemostemix" or the "Company") announces that, further to its April 9, 2021 news release announcing its Unit Offering, it has increased the aggregate gross proceeds of its Unit Offering to $1,050,000, reduced the Unit price to $0.35 per Unit, and reduced the exercise price of the Warrants to $0.40 per Common Share. In addition, further to its April 9, 2021 news release...

    2021-04-26 9:00 AM EDT
  • Hemostemix Announces Completion of Phase II Clinical Trial Subject Follow Up and HMTXF Up-list

    Calgary, Alberta--(Newsfile Corp. - April 23, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ‎‎(FSE: 2VFO.F) ("Hemostemix" or the "Company") is pleased to announce the completion of the Phase II Clinical Trial subject follow up, as the 65th (final) subject has completed their last follow-up visit. With subject follow up now completed the Company is shifting its focus to completing the data analyses and reporting associated with finalizing their Phase II Clinical Trial. In addition, the Company has...

    2021-04-23 3:00 PM EDT
  • Hemostemix Announces a $2,500,000 Lead Order and its Clinical Trial and Litigation Updates

    Calgary, Alberta--(Newsfile Corp. - April 9, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ‎‎(FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce that it has secured a $2,500,000 lead order from a director for Debenture Units, and intends to raise gross proceeds of up to $4,000,000 from the non-brokered Offerings of Units and Debenture Units, all as discussed below. The Company is progressing with completion of the phase II clinical trial data entry, source document ‎verification, and statistical...

    2021-04-09 8:56 PM EDT
  • Hemostemix Announces It Is Trading on the Frankfurt Stock Exchange and It Has Retained HE Capital Markets Ltd.

    Calgary, Alberta--(Newsfile Corp. - April 8, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0.F) ("Hemostemix" or the "Company") is pleased to announce it is trading on the Frankfurt Stock Exchange under symbol 2VF0.F and it has engaged HE Capital Markets Ltd. (HE Capital) to design and implement a North American and European multimedia digital advertising campaign on certain investor-focused and financial market websites. HE Capital will also provide other media communications services to raise the company's overall...

    2021-04-08 8:55 AM EDT
  • Hemostemix Announces Clinical Trial Update and Contract with GlobeX Data to Encrypt its Communications with Regulatory Authorities

    Calgary, Alberta--(Newsfile Corp. - March 18, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce that it has contracted two additional clinical research associates, is completing the remaining data entry and source document verifications, and has subscribed with GlobeX Data Ltd. (OTCQB: SWISF) (CSE: SWIS) (FSE: GDT), to encrypt its email communications with regulatory authorities in a secure portal.Sekur is one app that bundles encrypted email, messaging and file transfer into one solution...

    2021-03-18 9:22 AM EDT
  • Hemostemix Announces the Protocol First Contract and Warrant Repricing Approval

    Calgary, Alberta--(Newsfile Corp. - February 11, 2021) - Hemostemix Inc. ("Hemostemix" or the "Company") (TSXV: HEM; OTC: HMTXF) is pleased to announce it has contracted Protocol First to provide it with source document verification services. Protocol First's P1 Source Upload solution, which runs alongside any EDC system, allows site coordinators to upload un-redacted source data at the click of a button. The CRA/monitor can remote monitor the data, mark it as reviewed, issue queries to the site, and create reports...

    2021-02-11 9:15 AM EST